{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+Infections&page=2", "query": { "condition": "Skin Infections", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+Infections&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-26T17:22:17.916Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05443321", "title": "Advancing Health Information Exchange (HIE) During Inter-hospital Transfer (IHT) to Improve Patient Outcomes", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Infections", "Heart Failure", "COPD Exacerbation", "Asthma", "Gastrointestinal Diseases", "Cardiac Event", "Arrythmia", "Renal Failure", "Renal Disease", "Rheumatic Diseases", "Urologic Diseases", "Neurologic Disorder", "Hematologic Diseases", "Oncology Problem", "Shock", "Critical Illness" ], "interventions": [ { "name": "Health Information Exchange (HIE) platform", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1006, "start_date": "2022-11-01", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-01-23", "last_synced_at": "2026-06-26T17:22:17.916Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05443321" }, { "nct_id": "NCT02629419", "title": "CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Candidiasis, Chronic Mucocutaneous" ], "interventions": [ { "name": "Amphotericin B", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Matinas BioPharma Nanotechnologies, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 4, "start_date": "2016-09-27", "completion_date": "2022-08-06", "has_results": true, "last_update_posted_date": "2024-08-07", "last_synced_at": "2026-06-26T17:22:17.916Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02629419" }, { "nct_id": "NCT03512275", "title": "A Study of Bermekimab in Patients With Hidradenitis Suppurativa", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hidradenitis Suppurativa" ], "interventions": [ { "name": "Bermekimab Monoclonal Antibody 400 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2018-06-20", "completion_date": "2019-01-14", "has_results": true, "last_update_posted_date": "2022-03-14", "last_synced_at": "2026-06-26T17:22:17.916Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03512275" }, { "nct_id": "NCT01878383", "title": "Identification of Herpes Simplex Virus (HSV) Shedding in the Female Genital Tract of Pregnant and Nonpregnant Women by GeneXpert PCR, Routine PCR, and Culture", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Herpes Simplex Virus" ], "interventions": [ { "name": "Genexpert assay", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "FEMALE", "summary": "19 Years and older · Female only" }, "enrollment_count": 12550, "start_date": "2014-01", "completion_date": "2019-12-31", "has_results": true, "last_update_posted_date": "2020-09-09", "last_synced_at": "2026-06-26T17:22:17.916Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01878383" }, { "nct_id": "NCT02595866", "title": "Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "AIDS-Related Non-Hodgkin Lymphoma", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Hepatocellular Carcinoma", "HIV Infection", "Kaposi Sarcoma", "Locally Advanced Lung Non-Small Cell Carcinoma", "Locally Advanced Malignant Solid Neoplasm", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Non-Hodgkin Lymphoma", "Recurrent Classic Hodgkin Lymphoma", "Recurrent Malignant Neoplasm", "Refractory Classic Hodgkin Lymphoma", "Refractory Malignant Neoplasm", "Stage III Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Unresectable Melanoma" ], "interventions": [ { "name": "Antiretroviral Therapy", "type": "DRUG" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2016-04-04", "completion_date": "2024-03-25", "has_results": true, "last_update_posted_date": "2024-08-09", "last_synced_at": "2026-06-26T17:22:17.916Z", "location_count": 12, "location_summary": "Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02595866" }, { "nct_id": "NCT00248547", "title": "Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "aprepitant", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "ondansetron", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2004-05", "completion_date": "2009-01", "has_results": true, "last_update_posted_date": "2017-05-09", "last_synced_at": "2026-06-26T17:22:17.916Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00248547" }, { "nct_id": "NCT00379938", "title": "B-19 Parvovirus Vaccine Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Parvovirus B19 Infection" ], "interventions": [ { "name": "VAI-VP705 (parvovirus B-19 vaccine)", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" }, { "name": "MF-59", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 43, "start_date": "2006-08", "completion_date": "2008-10", "has_results": false, "last_update_posted_date": "2011-08-15", "last_synced_at": "2026-06-26T17:22:17.916Z", "location_count": 3, "location_summary": "Baltimore, Maryland • Cincinnati, Ohio • Houston, Texas", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00379938" }, { "nct_id": "NCT00785200", "title": "MRSA Colonization and Control in the Dallas County Jail", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Methicillin-resistant Staphylococcus Aureus", "Skin Diseases, Infectious", "Soft Tissue Infections" ], "interventions": [ { "name": "Chlorhexidine", "type": "OTHER" }, { "name": "Water", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4194, "start_date": "2009-01", "completion_date": "2010-02", "has_results": false, "last_update_posted_date": "2013-06-12", "last_synced_at": "2026-06-26T17:22:17.916Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00785200" }, { "nct_id": "NCT05892614", "title": "Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Interstitial Lung Disease" ], "interventions": [ { "name": "efzofitimod 450 mg", "type": "DRUG" }, { "name": "efzofitimod 270 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "aTyr Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2023-10-26", "completion_date": "2026-04", "has_results": false, "last_update_posted_date": "2025-05-07", "last_synced_at": "2026-06-26T17:22:17.916Z", "location_count": 15, "location_summary": "Los Angeles, California • San Diego, California • Miami, Florida + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05892614" }, { "nct_id": "NCT00002000", "title": "A Study to Compare the Efficacy and Safety of Valacyclovir Hydrochloride ( 256U87 ) Versus Acyclovir in the Treatment of Recurrent Anogenital Herpes Infections in HIV Infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Herpes Simplex", "HIV Infections" ], "interventions": [ { "name": "Valacyclovir hydrochloride", "type": "DRUG" }, { "name": "Acyclovir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Glaxo Wellcome", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-06-26T17:22:17.916Z", "location_count": 22, "location_summary": "Mobile, Alabama • San Francisco, California • Denver, Colorado + 17 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "West Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002000" } ] }